Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Assets Average: 2015-2025

Historic Assets Average for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $460.5 million.

  • ImmunityBio's Assets Average rose 13.87% to $460.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.5 million, marking a year-over-year increase of 13.87%. This contributed to the annual value of $443.7 million for FY2024, which is 2.37% up from last year.
  • Latest data reveals that ImmunityBio reported Assets Average of $460.5 million as of Q3 2025, which was up 30.49% from $352.9 million recorded in Q2 2025.
  • ImmunityBio's 5-year Assets Average high stood at $468.4 million for Q4 2023, and its period low was $215.4 million during Q1 2021.
  • Moreover, its 3-year median value for Assets Average was $373.8 million (2024), whereas its average is $391.9 million.
  • In the last 5 years, ImmunityBio's Assets Average skyrocketed by 99.28% in 2022 and then fell by 24.13% in 2025.
  • ImmunityBio's Assets Average (Quarterly) stood at $341.7 million in 2021, then climbed by 4.68% to $357.6 million in 2022, then skyrocketed by 30.98% to $468.4 million in 2023, then fell by 20.21% to $373.8 million in 2024, then rose by 13.87% to $460.5 million in 2025.
  • Its Assets Average stands at $460.5 million for Q3 2025, versus $352.9 million for Q2 2025 and $343.3 million for Q1 2025.